Limits...
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.

Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C - Lancet Infect Dis (2011)

Bottom Line: Late relapses were noted in three of 175 patients in the culture-confirmed chloramphenicol group and two of 177 in the gatifloxacin group.There were no culture-positive relapses after day 62. 99 patients (24%) experienced 168 adverse events in the chloramphenicol group and 59 (14%) experienced 73 events in the gatifloxacin group.Wellcome Trust.

View Article: PubMed Central - PubMed

Affiliation: Oxford University Clinical Research Unit-Patan Academy of Health Sciences, Kathmandu, Nepal.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3108101&req=5

fig2: Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients

Mentions: The secondary outcome measures, which included fever clearance time (median 3·95 days in the chloramphenicol group and 3·90 in the gatifloxacin group) and time to relapse until day 31 or day 62 also showed no significant difference between the groups (table 2). Only syndromic relapses were documented between day 62 and 6 months. Figure 2 shows the Kaplan-Meier estimates for the time to treatment failure, fever clearance, and relapse.


Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.

Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C - Lancet Infect Dis (2011)

Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3108101&req=5

fig2: Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients
Mentions: The secondary outcome measures, which included fever clearance time (median 3·95 days in the chloramphenicol group and 3·90 in the gatifloxacin group) and time to relapse until day 31 or day 62 also showed no significant difference between the groups (table 2). Only syndromic relapses were documented between day 62 and 6 months. Figure 2 shows the Kaplan-Meier estimates for the time to treatment failure, fever clearance, and relapse.

Bottom Line: Late relapses were noted in three of 175 patients in the culture-confirmed chloramphenicol group and two of 177 in the gatifloxacin group.There were no culture-positive relapses after day 62. 99 patients (24%) experienced 168 adverse events in the chloramphenicol group and 59 (14%) experienced 73 events in the gatifloxacin group.Wellcome Trust.

View Article: PubMed Central - PubMed

Affiliation: Oxford University Clinical Research Unit-Patan Academy of Health Sciences, Kathmandu, Nepal.

Show MeSH
Related in: MedlinePlus